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PUK25
QUality Of life in WOmen Patients With Urinary incOntinence in 
slOvaKia
Gerlichova K, Bielik J, Papsova D, Melus V
Trencin University, Trencin, Slovak Republic
Objectives: The prevalence of urinary incontinence (UI) in women in Slovakia is 
about 240 000 cases and has an increasing trend. Only 5 % of them were diagnosed 
by visiting urology or gynecology outpatient department. The objective of this paper 
was to find out the level of QoL in women with UI in Slovakia. MethOds: The 
primary method used for the analysis of QoL was the combined questionnaire 
consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1- International 
Consultation on Incontinence (ICIQ-SF): 4 items, B2- characteristics of UI: 23 items), 
C. Quality of life with dominant numeric scale (13 items), D. Socio-economic part (9 
items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 112 patients 
in the examined group from the160 asked to fill the questionnaire. The average age 
was 61 years. Results: Present level of QoL was identified as 6,60 on the scale from 
1 to 10 (1- the worst,10 –the best), while in the time of the UI diagnosis it was 5,10. 
QoL was 8,10 in the time without UI and 9,40 in the total optimal state of health. 
Comparative to the QoL was examined the ability to work (AW), too. Present level 
of AW was identified as 6,50, while in the time of the BC diagnosis it was 5,50. AW 
was 8.20 in the time without UI and 9,40 in the total optimal state of health. The 
impact of treatment on QoL was 7,60 and the disease had impact 7,40 on family 
QoL. The average income was 465,04 € and the willingness to pay for 1 month of 
complete health was in average 391,06 € . cOnclusiOns: The disease had a sig-
nificant impact on patients´s QoL. The treatment of UI had a significant impact on 
increasing QoL of patients.
PUK26
the QUality Of life Of Parents Of Pediatric Kidney transPlantatiOn 
Patients
Hamasaki Y1, Tazaki M2, Yamaguchi T2, Shishido S1
1Omori Hospital, Tokyo, Japan, 2Toho University, Tokyo, Japan
Objectives: The purpose of the study is to investigate how the QOL of parents 
whose child had received pediatric kidney tranplantation(KT) would change by 
delivering questionnaires for four times a year. MethOds: The QOL of thirty-one 
parents with a mean age of 38.5 yrs old (30 mothers, 1 father) whose child received 
KT at Toho Ohmori Hospital in Tokyo from May 2012 to March 2015 was measured 
using WHOQOL, GHQ, and VAS for four times; before, one month, three months, 
one year after KT. The mean age of receipient patients was 5.8 yrs old (18 boys, 13 
girls). Congenital anomalies of the kidney and urinary tract were most frequent 
primary diseases. Among them twenty-two children received dialysis before KT, 
and nine received preemtive KT. Results: Based on the results of WHOQOL, the 
QOL of parents dropped with a statistical difference one month after KT, compared 
with before KT (p= 0.042), but rose at three months (p= 0.0073), and maintained 
until one year. The QOL of parents with child with frequent infections was statisti-
cally lower than those without any infectionat three months after KT (p= 0.448) 
and one year after KT (P= 0.0406). The QOL scores of nineteen donor parents had a 
statistically higher QOL before KT, but reversed at one month after KT particurally 
in physical domain of WHOQOL, but became higher again at three month after 
KT, compared with the rest of parents. cOnclusiOns: The QOL of the parents 
would change in the process recovery of child, and with infection or other medi-
cal problems occurred, QOL reflected it, but three months after KT, QOL rose as 
high as before KT.
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nOctUria WOrK PrOdUctivity and activity imPairment cOmPared tO 
Other cOmmOn chrOnic diseases: a systematic revieW
Miller PS1, Andersson FL2
1MILLER ECONOMICS LTD., Alderley Edge, UK, 2Ferring Pharmaceuticals A/S, Copenhagen, 
Denmark
Objectives: Nocturia is defined by the International Continence Society as 
the need to void one or more times during the night, with each of the voids 
preceded and followed by sleep. The chronic sleep disturbance and sleep depri-
vation suffered by nocturia patients impacts their entire health-related quality 
of life, compromising both mental and physical well-being. This review aims 
to better characterise the societal burden of nocturia by comparing published 
data from nocturia patients with those of 12 other common chronic conditions, 
specifically focussing on the impact on work productivity and activity impair-
ment, as measured by the WPAI (Work Productivity and Activity Impairment) 
instrument. MethOds: Systematic searches of Medline and the WPAI database 
returned 241 publications, after removal of duplicates, 178 publications were 
screened, and 79 evaluable studies were identified for inclusion in the review. 
Most exclusions were due to duplicate publication of the same study or insuf-
ficient WPAI data presented. Data extraction recorded study and summary-level 
patient characteristics and all reported WPAI data on overall work productiv-
ity impairment and overall activity impairment. Results: The number of 
evaluable studies, the number of different disease-specific subgroups with 
WPAI data and the range of overall work productivity impairment reported, 
respectively, were as follows: nocturia (3, 10, 14-39%); overactive bladder (6, 6, 
11-41%); irritable bowel syndrome/ constipation (11, 13, 25-40%); GERD (13, 15, 
13-33%); asthma/ allergies (11, 15, 6-40%); COPD (7, 9, 21-42%); sleep problems (2, 
3, 12-37%); arthritis (12, 16, 21-69%); pain (8, 9, 29-52%); depression (4, 5, 15-43%); 
and gout (2, 2, 20-37%). cOnclusiOns: The overall work productivity impair-
ment of nocturia is substantial and found to be similar to several other more 
frequently researched common chronic diseases. Greater awareness of the bur-
den of nocturia, a highly bothersome and prevalent condition, will help policy-
makers and healthcare decision-makers to provide appropriate management of 
nocturia.
‘waking to void 1 or more times a night followed by sleep’, is reported as being the 
most bothersome of these symptoms. The most frequent cause of nocturia is noctur-
nal polyuria (NP, overproduction of urine during the night defined as ≥ 33% of total 
urine volume). While there are well-known negative effects of nocturia on Health-
related Quality of Life, there is limited information on the relationship between NP 
disease severity, as defined by the number of nightly voids, and utility. MethOds: 
Data were drawn from a randomised clinical trial of desmopressin (an antidiuretic) 
combined with tolterodine (an antimuscarinic agent) in women with overactive 
bladder and nocturia (ClinTrials.gov identifier: NCT01729819). Patients were required 
to have 2 or more nightly voids to be included in the trial, as this has been shown 
to be a clinically-relevant threshold for patient bother. We selected the subgroup 
of patients with NP who completed the Nocturia Impact Diary (a disease-specific 
HRQoL instrument, ranging from 0-100 where low values imply better QoL) and 
the generic EQ-5D-5L (n= 41). The utility analysis was adjusted for age, body mass 
index, baseline number of nightly voids and number of comorbidities. Results: The 
adjusted mean EQ-5D index for 2-3 voids was 0.87 and for 4 or more nightly voids 
0.83 (ns). The adjusted EQ-5D VAS values were similar at 80.5 and 80.6. Unadjusted 
index utility values were 0.88 and 0.81, respectively. The Nocturia Impact Diary total 
scores were 41.5 and 46.8 for the two groups, respectively. cOnclusiOns: The gen-
eral disadvantage of the EQ-5D is that it is relatively insensitive to urinary diseases. 
This analysis suggests, however, that there is a relationship between nocturnal 
polyuria (and nocturia) disease severity, HRQoL and utility.
PUK23
validatiOn Of the Overactive Bladder QUestiOnnaire (OaB-Q; 1-WeeK 
recall) in medically cOmPlex elderly adUlts With Overactive 
Bladder
Barsdorf AI1, Carlsson M1, Bushmakin AG2, Quinn S1, Cappelleri JC2, Pleil A3
1Pfizer, Inc, New York, NY, USA, 2Pfizer, Inc, Groton, CT, USA, 3Pfizer, Inc, San Diego, CA, USA
Objectives: To confirm the factor structure and evaluate the reliability, validity, 
and responsiveness of the OAB-q in medically complex elderly with overactive 
bladder (OAB). MethOds: Post-hoc analyses were conducted using data from a 
12-week clinical trial for urgency urinary incontinence (UUI; N= 566). Structure of 
the OAB-q was evaluated using a confirmatory factor analysis. Cronbach’s coef-
ficient alpha (CCA) was used to assess reliability. Convergent validity was exam-
ined using Pearson’s and Spearmen Product-Moment correlations. Known-groups 
validity was assessed by evaluating differences in OAB-q scores in patients cat-
egorized according to UUI severity (mild, moderate, severe) and Patient Perception 
of Bladder Condition (PPBC) severity (Some Moderate Problems, Severe to Many 
Severe Problems). Effect size was used to examine responsiveness of the OAB-q, 
and an anchor-based approach was used to estimate the clinically important dif-
ference. Results: Participants were mainly female (82.2%) and white (85.9%) with 
a mean age of 75.0 (± 6.4) years. Bentler’s Comparative Fit Index was satisfactory 
(0.90), path coefficients were statistically significant (t-values > 1.96), and all stand-
ardized path coefficients were > 0.40, indicating that a second-order measurement 
model with 5 domains and one aggregated domain holds true in the medically com-
plex elderly population. OAB-q domains demonstrated good internal consistency 
(CCAs > 0.7). Convergent validity was supported by moderate correlations (0.4 – 0.7) 
between OAB-q domains and other related patient-reported outcomes. Significant 
differences in OAB-q domain scores between groups of different severity based on 
UUI and PPBC provided evidence of known-groups validity. Responsiveness was 
demonstrated by statistically significant and clinically relevant differences in mean 
scores for the OAB-q domains over time between Baseline and Week 12 with effect 
sizes of those differences of about 0.2. cOnclusiOns: The OAB-q has reliability, 
sound concurrent and discriminative validity with other measures, responsiveness 
to treatment, and is fit for purpose in medically complex elderly patients with OAB.
PUK24
health-related QUality Of life (hrQOl) measUres in aUtOsOmal 
dOminant POlycystic Kidney disease (adPKd)
Oberdhan D1, Krasa HB1, Schaefer C2, Cole JC3
1Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, 2Covance 
Market Access Services Inc., Gaithersburg, MD, USA, 3Pharmaceutical Product Development, San 
Diego, CA, USA
Objectives: ADPKD imposes substantial burdens on HRQoL at all stages of the dis-
ease. Few studies have examined disease impacts and symptomatology on HRQoL. 
This analysis aimed to assess whether disease-specific questionnaires allow for 
improved assessment of HRQoL in ADPKD. MethOds: In a large global observa-
tional study of 3,409 subjects, patient-reported outcomes (PRO) instruments (includ-
ing SF-12v2, EQ-5D, ADPKD-IS) were completed in 6-month intervals. Scores were 
calculated at Baseline and longitudinally, overall and by chronic kidney disease 
(CKD) stage. Results: The overall population scores were normal/near normal 
regardless of instrument with little change overtime (mean score at Baseline and 
18 months): SF-12 Mental Component Summary score (MCS) 50.15 to 49.77, SF-12 
Physical Component Summary score (PCS) 49.94 to 49.12; EQ-5D US Index 0.91 to 
0.90; ADPKD-IS Physical 1.59 to 1.66, Emotional 1.78 to 1.79, Fatigue 1.90 to 1.95. 
Only the SF-12 PCS and ADPKD-IS instruments were able to differentiate between 
early and late stage disease at Baseline (CKD1 vs CKD4 at baseline (SD): PCS 52.22 
(8.41) vs 46.79 (9.89), MCS 49.66 (9.90) vs 51.09 (9.63), EQ-5D US Index 1.06 (0.25) 
vs 1.13 (0.34), ADPKD-IS Physical 1.47 (0.82) vs 1.83 (0.88), Emotional 1.72 (0.88) vs 
2.07 (0.91), Fatigue 1.77 (1.03) vs 2.25 (1.23)). Longitudinal changes (Baseline and 18 
months) could only be measured in later disease stages. Changes in EQ-5D and 
SF-12 were driven by impacts on overall health state. cOnclusiOns: The disease-
specific ADPKD-IS questionnaire was more sensitive to HRQoL in a cross-sectional 
analysis by disease severity vs all generic HRQoL instruments except SF-12 PCS. 
In a slowly progressing disease like ADPKD, observations of longitudinal change 
in HRQoL will require longer follow-up. These results support that ADPKD disease 
impacts are incapable of being measured by blunt generic tools.
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1Ingress Health, Wismar, Germany, 2IPAM (in the past), Wismar, Germany, 3IPAM, Wismar, 
Germany, 4Merck Sharp & Dohme Co., Whitehouse Station, NJ, USA, 5Pharmerit US Bethesda, 
Bethesda, MD, USA, 6AOK PLUS, Dresden, Germany, 7AOK Plus, Dresden, Germany
Objectives: We aimed to (1) describe the real-world treatment of UTIs in a T2DM 
population, (2) investigate UTI related healthcare resource use, (3) assess treat-
ment costs associated with UTI, and (4) identify factors which may predict UTI-
related treatment costs. MethOds: We analysed an anonymized dataset from a 
regional German healthcare fund (AOK PLUS) including all continuously insured 
T2DM-prevalent patients from 2010-2012. Health care resource use was reported 
per UTI episode. A UTI episode was identified through coded outpatient/inpatient 
UTI diagnoses (ICD-10 N39.0) and, in case of recurrent diagnoses, prescribed anti-
biotics for UTI treatment. Results: A total of 456,586 T2DM patients (mean age of 
73.8 years, 56.3% female, mean CCI of 7.3, mean observational period of 665.5 days) 
was included. We identified 48,337 UTI episodes. During an observed UTI episode, 
patients visited with a median/mean of 1.0/0.8 times a GP and 0.0/0.3 times an 
urologist. In 6.7% of the cases, an inpatient treatment was caused by a UTI with a 
median/mean length of stay of 7.0/8.7 days. In 74.8% of the observed UTI episodes, 
antibiotics labelled for this disease were prescribed (mean prescribed DDD 10.5 
days). Mean/median costs directly associated with UTI treatment (bottom-up costs) 
were 315.90€ /102.28€ per UTI episode. Factors significantly increasing UTI-related 
direct bottom costs were age, female gender, worse CKD status (5/5), CCI, and at 
least one previous UTI infection in the reference period. In an additional top-down 
cost analysis, annual all-cause cost per patient year were 5,519 € higher in the UTI 
group compared to T2DM patients not having experienced an UTI. This translated 
into a UTI-related marginal cost-increasing effect of 3,916€ per patient year in a 
multivariable Gamma regression analysis. cOnclusiOns: Given that worldwide 
increasing prevalence of T2DM, the incidence of UTI infection in T2DM represents 
substantial resource use/cost burden for healthcare systems.
PUK32
aUtOsOmal POlycystic Kidney disease (adPKd): cOsts and resOUrce 
UtilisatiOn in the nOrdic cOUntries
Eriksson D1, Karlsson L1, Eklund O1, Dieperink H2, Honkanen E3, Melin J4, Selvig K5, 
Lundberg J6
1Quantify Research, Stockholm, Sweden, 2Odense University Hospital, Odense, Denmark, 3Helsinki 
University Central Hospital, Helsinki, Finland, 4Uppsala University Hospital, Uppsala, Sweden, 
5Vestre Viken Hospital Trust, Drammen, Norway, 6Otsuka Pharma Scandinavia, Stockholm, 
Sweden
Objectives: There is limited real-world information on resource utilisation, costs 
and productivity in patients with ADPKD. The objective of this study was to esti-
mate the annual direct and indirect costs of patients with ADPKD by severity of the 
disease [chronic kidney disease (CKD) stages 1–3, 4–5, dialysis, and transplant recipi-
ents], and describe the resource utilisation during the 12-month period around dial-
ysis initiation and transplant procedure, respectively. MethOds: A cross-sectional 
study of ADPKD patients was undertaken April–December 2014 in Denmark, Finland, 
Norway and Sweden. Data on medical resource utilisation were extracted from med-
ical charts and patients were asked to complete a self-administered survey, which 
included the Work Productivity and Activity Impairment Questionnaire. Results: A 
total of 266 patients were contacted, 243 (91%) of whom provided consent to partici-
pate in the study. Average total annual costs amounted to € 9,919 in CKD 1–3, € 16,761 
in CKD 4–5, € 74,015 in dialysis patients and € 31,496 in transplant recipients. Indirect 
costs were substantial in earlier stages of the disease, accounting for 72% and 73% 
of total costs in the CKD 1–3 and CKD 4–5 strata, respectively. Direct medical costs 
amounted to € 60,514 in dialysis patients and € 17,773 in transplant recipients. Among 
those who were employed, the overall work productivity loss ranged between 9% 
in CKD stage 1–3 to 42% in dialysis patients. An average of 16.5 hospital days and 
10.4 outpatient visits were observed in the 12-month period around dialysis initia-
tion. Around the transplant procedure, the average number of hospital days and 
outpatient visits were 29.9 and 16.9, respectively. cOnclusiOns: ADPKD is a pro-
gressive disease associated with increasing costs as the patient progresses to CKD 
stage 4–5, dialysis and transplant. Substantial savings and productivity gains could 
be made by delaying the progression of ADPKD to end stage renal disease.
PUK33
healthcare resOUrce cOnsUmPtiOn and cOsts BefOre and after 
Kidney transPlantatiOn in lOmBardy, italy
Roggeri DP1, Roggeri A1, Zocchetti C2, Conte F3
1ProCure Solutions, Nembro (BG), Italy, 2Lombardy Region, Milan, Italy, 3S. Uboldo Hospital, 
Cernusco sul Naviglio (MI), Italy
Objectives: Aim of the present study was to evaluate, through the analysis of 
administrative databases, healthcare resource consumption and costs in charge 
to the Regional Health Service (RHS) for patients receiving kidney transplanta-
tion. MethOds: All data recorded in the regional administrative databases regard-
ing subjects resident in Lombardy (one of the Italian Regions, with about 9,700,000 
inhabitants) who received kidney transplantation in 2011 were extracted. Direct 
healthcare costs in charge to the RHS for these subjects for the 12 months preced-
ing and following transplantation were estimated (drugs, hospitalizations, diag-
nostic/therapeutic procedures). Results: In 2011, 276 subjects received kidney 
transplantation, 268 of which survived for the following 12 months. Administrative 
data were available for 264 of these subjects (67.8% males, mean age 49.4). Among 
those patients who survived one year after transplantation, the per-patient yearly 
cost before transplantation amounted to 36,746€ (11.6% for drugs, 81.2% for diag-
nostic/therapeutic procedures and 7.2% for hospitalizations). Dialysis accounted 
for 91% of all costs for diagnostic/therapeutic procedures. In the year following 
transplantation, the per-patient cost amounted to 43,806€ (25.8% for drugs, 15.8% 
for diagnostic/therapeutic procedures and 58.4% for hospitalizations). The average 
per-patient cost of transplantation intervention was 21,183€ (82.7% of total cost 
of hospitalizations). The average cost of the last year of life of those patients who 
died within 12 months after transplantation was 79,362€ /patient (68.1% of which 
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dOes OUt-Patient medical insUrance POlicy WOrK amOng cKd 
Patients in nOn-dialysis Phases? evidence frOm tWO samPle cities in 
china
Wu J, Liu J, Zhu B, Mao Y
Xi’an Jiaotong University, Xi’an, China
Objectives: Chronic kidney disease (CKD) has become a major public health 
problem in China. Two sample cities, Qingdao, which has been providing out-
patient service with CKD patients in non-dialysis phases, and Shenyang, which 
has not provided the service, are selected as samples to discuss the policy effect 
of out-patient medical insurance. MethOds: CKD patient data collected in medi-
cal insurance administrative agencies of two sample cities in 2009 and 2010 are 
analyzed through discriptive statistics and independent sample T-test. Results: 
1) For kidney dialysis (KD) patients, out-patient growth rates of Qingdao and 
Shenyang are 8.15% and 15.93% respectively, and average ages are 56.14 and 
57.67 (P= 0.516); in-patient growth rates of Qingdao and Shenyang are -5.28% and 
16.01% respectively, and average ages are 60.56 and 58.88 (p= 0.000). 2) For renal 
transplantated (RT) recipients, out-patient growth rates of Qingdao and Shenyang 
are 7.80% and 8.15% respectively, and average ages are 48.71 and 48.73 (p= 0.172); 
in-patient growth rates of Qingdao and Shenyang are -6.98% and 2.65% respec-
tively, and average ages are 46.79 and 50.44 (p= 0.000). 3) On medical insurance 
fund expenditure, expenditure growth rates of KD out-patients and in-patients 
of Qingdao are -4.80% and -11.59% respectively, and those of Shenyang are 22.51% 
and 36.52%; expenditure growth rates of out-patient and in-patient RT recipients 
of Qingdao are -5.50% and -25.60% respectively, and those of Shenyang are 6.48% 
and -3.79%. cOnclusiOns: 1) Out-patient insurance creates a positive effect on 
controlling the excessive growth of the number of KD patients, while the effect 
is not so significant on the number of RT recipients. 2) Out-patient insurance 
produces effective results on controlling the rapid growth of medical insurance 
fund expenditure scale of KD patients, while the effect is not so significant of RT 
recipients. 3) Average ages of KD patients have not been decreased effectively 
because of the short period of policy implementation.
PUK29
a cOncePt fOr Best-Practice in theraPeUtic drUg mOnitOring (tdm) 
fOr Kidney transPlant (K-tx): resUlts frOm Q-PeriOr stUdy
Ossa D1, Becker G2, Bayer S2
1Novartis Pharma, Basel, Switzerland, 2Q-Perior AG, Zurich, Switzerland
Objectives: The objective of this study was to establish current practice in TDM 
in K-Tx in a real-world clinical setting, and to develop a best-practice concept to 
improve patient care. MethOds: TDM processes for transplanted patients were col-
lected at 13 centers in 5 countries between January 2015 and June 2015. More than 35 
Interviews with physicians, nurses and lab assistants were combined with observa-
tion of relevant steps during standard examination sessions. Duration of each main 
step to adjust the patient medication dose was recorded. Also dependencies from 
outside variables were recorded. Results: Several process patterns were identified. 
Main observed differences among centers were process steps and inefficiencies in 
exam setup and time required getting test results. The time gap between taking blood 
samples and availability of results leads to long patient stay and/or multiple visits or 
contacts with the patient (blood test, examination, result communication). Average 
time for patients in a center was 2:12 hours with a large range from 0:49 hours to 
6:22 hours. Process time for blood drawing, examinations and results communica-
tion (excluding lab processing) was on average 30 min ranging from 12 min to 52 
min. Complexity and time to get the results could be improved if a near-patient-test 
(NPT) scenario would be available while others are subject to normal process improve-
ments. cOnclusiOns: Results suggest that improvements could be made in all types 
of scenarios. Especially fast availability of test results in a NPT scenario could reduce 
complexity and facilitate the development of an improved process setup.
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exPeriences With Price cOmPetitiOn Of BiOsimilar drUgs in hUngary 
in case Of erythrOPOietin PrOdUcts
Nagy Z1, Hornyák L2, Tálos Z2, Endrei D1, Ágoston I1, Csákvári T3, Boncz I1
1University of Pécs, Pécs, Hungary, 2Csolnoky Ferenc Hospital, Veszprém, Hungary, 3University of 
Pécs, Zalaegerszeg, Hungary
Objectives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of erythropoietin (ESA) prod-
ucts. MethOds: Data derived from the nationwide pharmaceutical database of 
Hungarian National Health Insurance Fund Administration. We analysed how the 
number of patients treated by erythropoietin products changed before (01.07.2011.-
30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed 
in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4,482 
patients received erythropoietin treatment, while in the first 12 months after the bid 
4,545 patients, resulting in a 1.4 % increase. The second 12 months after the bid 4,644 
patients received erythropoietin treatment, resulting in a 3.6 % increase. Before the 
biosimilar bid, the NHIFA spent 2.33 billion Hungarian Forint (HUF) health insurance 
reimbursement for ESA products, which decreased by 47 % to 1.23 billion HUF in the 
first year after biosimilar bid. cOnclusiOns: The analyses of the Hungarian price 
competition bid of biosimilar products showed a minimal decline in the number of 
patients under treatment by erythropoietin products while the health insurance 
reimbursement of these drugs significantly decreased.
PUK31
disease BUrden and cOsts assOciated With Urinary tract infectiOns 
in tyPe 2 diaBetes mellitUs Patients: an analysis Based On a large 
samPle Of 456,586 german Patients
Wilke T1, Boettger B2, Berg B3, Williams J4, Botteman M5, Yu S4, Fuchs A6, Maywald U7
